Fresenius Medical Care AG & Co. KGaA (FMS) 10-Year Financial Performance & Capital Metrics

FMS • • Industrial / General

HealthcareHealthcare FacilitiesSpecialized Medical ServicesDialysis Services

AboutFresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.Show more

Revenue $19.34B -0.6%
EBITDA $3.13B +0.4%
Net Income $538M +7.8%
EPS (Diluted) 0.92 +8.2%
Gross Margin 24.6% -2.8%
EBITDA Margin 16.21% +1.0%
Operating Margin 7.2% +2.3%
Net Margin 2.78% +8.5%
ROE 3.52% +6.7%
ROIC 4.09% +5.2%
Debt/Equity 0.70 -14.3%
Interest Coverage 3.42 +6.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 7/9
✓High quality earnings: Operating CF exceeds net income
✓Healthy dividend yield of 2.8%
✓Trading at only 0.8x book value

✗Weaknesses

✗Weak 3Y average ROE of 3.8%
✗Profits declining 14.8% over 5 years

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y4.03%

5Y2.04%

3Y3.15%

TTM2.1%

Profit (Net Income) CAGR

10Y-4.58%

5Y-14.82%

3Y-17.82%

TTM9%

EPS CAGR

10Y-4.31%

5Y-7.38%

3Y3.49%

TTM87.3%

ROCE

10Y Avg9.29%

5Y Avg6.23%

3Y Avg5.05%

Latest5%

Peer Comparison

Dialysis Services

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
FMSFresenius Medical Care AG & Co. KGaA	12.54B	21.63	23.51	-0.61%	3.66%	5.16%	13.45%	0.70
DVADaVita Inc.	7.47B	105.84	9.86	5.56%	5.8%	50.51%	19.63%	5.77

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	15.31B	17.03B	17.78B	16.55B	17.48B	17.86B	17.62B	19.4B	19.45B	19.34B
Revenue Growth %	0.18%	0.11%	0.04%	-0.07%	0.06%	0.02%	-0.01%	0.1%	0%	-0.01%
Cost of Goods Sold+	10.43B	11.53B	11.78B	11.39B	12.08B	12.32B	12.85B	14.5B	14.53B	14.58B
COGS % of Revenue	0.68%	0.68%	0.66%	0.69%	0.69%	0.69%	0.73%	0.75%	0.75%	0.75%
Gross Profit+	4.88B	5.5B	6B	5.16B	5.4B	5.54B	4.77B	4.89B	4.93B	4.76B
Gross Margin %	0.32%	0.32%	0.34%	0.31%	0.31%	0.31%	0.27%	0.25%	0.25%	0.25%
Gross Profit Growth %	0.19%	0.13%	0.09%	-0.14%	0.05%	0.03%	-0.14%	0.03%	0.01%	-0.03%
Operating Expenses+	2.78B	3.05B	3.71B	3B	3.13B	3.23B	2.92B	3.38B	3.56B	3.36B
OpEx % of Revenue	0.18%	0.18%	0.21%	0.18%	0.18%	0.18%	0.17%	0.17%	0.18%	0.17%
Selling, General & Admin	2.65B	2.9B	3.58B	2.87B	3.03B	3.13B	2.77B	3.17B	3.2B	3.14B
SG&A % of Revenue	0.17%	0.17%	0.2%	0.17%	0.17%	0.18%	0.16%	0.16%	0.16%	0.16%
Research & Development	128.05M	154.04M	131M	134M	168.03M	193.77M	220.78M	228.62M	231.97M	183.49M
R&D % of Revenue	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%
Other Operating Expenses	0	0	0	0	-73.68M	-94.52M	-72.87M	-17.06M	127.26M	37.95M
Operating Income+	2.13B	2.51B	2.36B	3.04B	2.27B	2.3B	1.85B	1.51B	1.37B	1.39B
Operating Margin %	0.14%	0.15%	0.13%	0.18%	0.13%	0.13%	0.11%	0.08%	0.07%	0.07%
Operating Income Growth %	0.15%	0.18%	-0.06%	0.29%	-0.25%	0.02%	-0.2%	-0.18%	-0.09%	0.02%
EBITDA+	2.78B	3.21B	3.1B	3.76B	3.86B	4.09B	3.48B	3.35B	3.12B	3.13B
EBITDA Margin %	0.18%	0.19%	0.17%	0.23%	0.22%	0.23%	0.2%	0.17%	0.16%	0.16%
EBITDA Growth %	0.15%	0.15%	-0.04%	0.21%	0.03%	0.06%	-0.15%	-0.04%	-0.07%	0%
D&A (Non-Cash Add-back)	655.81M	701.54M	735.48M	724.85M	1.59B	1.79B	1.62B	1.84B	1.75B	1.74B
EBIT	2.23B	2.47B	2.41B	2.18B	2.33B	2.35B	1.93B	1.58B	1.46B	1.46B
Net Interest Income+	-352.82M	-363.41M	-364.82M	-301.06M	-429.44M	-368.02M	-280.43M	-292.48M	-336.42M	-335.47M
Interest Income	105.07M	63.4M	51.38M	147M	61.62M	41.96M	73.17M	67.66M	88.22M	71.58M
Interest Expense	457.89M	426.81M	416.2M	448M	491.06M	409.98M	353.6M	360.14M	424.64M	407.04M
Other Income/Expense	-352.82M	-363.41M	-364.82M	-301.06M	-429.44M	-368.02M	-280.43M	-292.48M	-336.42M	-335.47M
Pretax Income+	1.77B	2.12B	2.01B	2.74B	1.84B	1.94B	1.57B	1.22B	1.03B	1.06B
Pretax Margin %	0.12%	0.12%	0.11%	0.17%	0.11%	0.11%	0.09%	0.06%	0.05%	0.05%
Income Tax+	569.83M	649.42M	454M	511M	401.61M	500.56M	352.83M	324.95M	300.56M	316.06M
Effective Tax Rate %	0.53%	0.56%	0.64%	0.72%	0.65%	0.6%	0.62%	0.55%	0.48%	0.51%
Net Income+	941.19M	1.18B	1.28B	1.98B	1.2B	1.16B	969.31M	673.4M	499M	537.91M
Net Margin %	0.06%	0.07%	0.07%	0.12%	0.07%	0.07%	0.06%	0.03%	0.03%	0.03%
Net Income Growth %	0.1%	0.26%	0.08%	0.55%	-0.39%	-0.03%	-0.17%	-0.31%	-0.26%	0.08%
Net Income (Continuing)	1.21B	1.42B	1.55B	2.23B	1.44B	1.44B	1.22B	894.33M	732.46M	740.87M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	556.9M	616.47M	1.01B	1.14B	1.27B	1.12B	1.28B	1.46B	1.21B	1.19B
EPS (Diluted)+	1.57	1.87	2.08	3.23	1.35	1.31	0.83	0.57	0.85	0.92
EPS Growth %	0.1%	0.19%	0.11%	0.55%	-0.58%	-0.03%	-0.37%	-0.31%	0.49%	0.08%
EPS (Basic)	1.57	1.87	2.09	3.24	1.35	1.31	0.83	0.57	0.85	0.92
Diluted Shares Outstanding	610.53M	612.66M	614.57M	614.45M	887.33M	887.33M	1.17B	1.17B	586.83M	586.83M
Basic Shares Outstanding	610.19M	613.39M	615.28M	614.55M	888.24M	888.24M	1.17B	1.17B	587.06M	587.88M
Dividend Payout Ratio	0.25%	0.21%	0.23%	0.16%	0.3%	0.3%	0.4%	0.59%	0.66%	0.65%

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	6.19B	6.88B	6.37B	7.85B	7.17B	7.28B	7.97B	8.2B	8.7B	7.92B
Cash & Short-Term Investments	770.42M	974.72M	993.57M	2.27B	1.16B	1.26B	1.64B	1.46B	1.56B	1.34B
Cash Only	505.95M	708.88M	978.11M	2.15B	1.01B	1.08B	1.48B	1.27B	1.4B	1.18B
Short-Term Investments	264.47M	265.84M	15.46M	119.51M	155.55M	179.26M	159.18M	187.83M	154.37M	163.09M
Accounts Receivable	3.33B	3.7B	3.5B	3.43B	3.59B	3.26B	3.58B	3.72B	3.64B	3.41B
Days Sales Outstanding	79.31	79.31	71.85	75.67	75.02	66.7	74.17	69.99	68.26	64.35
Inventory	1.23B	1.34B	1.29B	1.47B	1.66B	1.9B	2.04B	2.3B	2.18B	2.07B
Days Inventory Outstanding	43.19	42.32	39.99	47	50.25	56.14	57.91	57.78	54.75	51.77
Other Current Assets	832.98M	800.16M	516.11M	603.63M	700.46M	817.6M	672.58M	682.6M	1.28B	1.06B
Total Non-Current Assets+	17.01B	18.62B	17.65B	18.4B	25.77B	24.41B	26.4B	27.55B	25.23B	25.64B
Property, Plant & Equipment	3.15B	3.58B	3.49B	3.84B	8.52B	8.19B	8.55B	8.34B	7.45B	7.26B
Fixed Asset Turnover	4.85x	4.76x	5.09x	4.31x	2.05x	2.18x	2.06x	2.33x	2.61x	2.66x
Goodwill	11.92B	12.99B	12.1B	12.21B	14.02B	12.96B	14.36B	15.79B	14.65B	15.17B
Intangible Assets	759.62M	805.55M	683.06M	681.33M	1.43B	1.38B	1.46B	1.52B	1.36B	1.37B
Long-Term Investments	593.62M	598.15M	647.01M	649.78M	696.87M	761.11M	786.9M	1.2B	1.08B	1.12B
Other Non-Current Assets	610.72M	683.12M	725.15M	1.02B	1.11B	1.13B	1.24B	702.46M	681.83M	720.02M
Total Assets+	23.2B	25.5B	24.03B	26.24B	32.93B	31.69B	34.37B	35.75B	33.93B	33.57B
Asset Turnover	0.66x	0.67x	0.74x	0.63x	0.53x	0.56x	0.51x	0.54x	0.57x	0.58x
Asset Growth %	0.11%	0.1%	-0.06%	0.09%	0.26%	-0.04%	0.08%	0.04%	-0.05%	-0.01%
Total Current Liabilities+	3.8B	5.3B	5.3B	6.27B	7.06B	6.06B	7.26B	6.47B	6.11B	5.66B
Accounts Payable	714.21M	839.63M	737.84M	795.05M	835.19M	827.39M	857.53M	951.58M	885.15M	984.32M
Days Payables Outstanding	24.99	26.57	22.86	25.47	25.23	24.51	24.37	23.95	22.24	24.64
Short-Term Debt	725M	1.3B	1.65B	2.5B	2.62B	1.09B	1.92B	1.34B	944.6M	577.38M
Deferred Revenue (Current)	0	1000K	1000K	0	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	765.91M	1.98B	2.48B	2.9B	2.44B	2.42B	2.75B	2.86B	2.99B	2.84B
Current Ratio	1.63x	1.30x	1.20x	1.25x	1.02x	1.20x	1.10x	1.27x	1.42x	1.40x
Quick Ratio	1.31x	1.05x	0.96x	1.02x	0.78x	0.89x	0.82x	0.91x	1.07x	1.03x
Cash Conversion Cycle	97.51	95.06	88.99	97.19	100.04	98.34	107.72	103.83	100.77	91.48
Total Non-Current Liabilities+	9.8B	9.15B	7.9B	7.07B	12.65B	13.3B	13.13B	13.84B	12.99B	12.14B
Long-Term Debt	7.18B	6.83B	5.79B	5.05B	6.46B	6.8B	6.65B	7.17B	6.96B	6.26B
Capital Lease Obligations	0	0	0	0	4.07B	3.88B	4.09B	4B	3.53B	3.5B
Deferred Tax Liabilities	571.21M	661.92M	467.54M	626.52M	739.7M	785.89M	868.45M	936.48M	750.29M	708.89M
Other Non-Current Liabilities	2.05B	1.66B	1.63B	1.4B	1.38B	1.83B	1.53B	1.72B	1.74B	1.63B
Total Liabilities	13.6B	14.45B	13.2B	13.34B	19.71B	19.36B	20.39B	20.3B	19.1B	17.8B
Total Debt+	7.96B	8.13B	7.52B	7.58B	13.82B	12.38B	13.32B	13.21B	12.08B	11B
Net Debt	7.46B	7.42B	6.55B	5.43B	12.81B	11.3B	11.84B	11.94B	10.67B	9.82B
Debt / Equity	0.83x	0.74x	0.69x	0.59x	1.04x	1.00x	0.95x	0.86x	0.81x	0.70x
Debt / EBITDA	2.86x	2.53x	2.43x	2.01x	3.58x	3.03x	3.83x	3.94x	3.87x	3.51x
Net Debt / EBITDA	2.68x	2.31x	2.11x	1.44x	3.32x	2.76x	3.41x	3.56x	3.42x	3.13x
Interest Coverage	4.65x	5.88x	5.68x	6.78x	4.62x	5.62x	5.24x	4.20x	3.22x	3.42x
Total Equity+	9.6B	11.05B	10.83B	12.9B	13.23B	12.33B	13.98B	15.45B	14.83B	15.77B
Equity Growth %	0.16%	0.15%	-0.02%	0.19%	0.03%	-0.07%	0.13%	0.11%	-0.04%	0.06%
Book Value per Share	15.72	18.04	17.62	21.00	14.91	13.90	11.93	13.17	25.27	26.87
Total Shareholders' Equity	9.04B	9.98B	9.82B	11.76B	11.96B	11.22B	12.7B	13.99B	13.62B	14.58B
Common Stock	354.12M	360.92M	308.11M	307.88M	304.44M	292.88M	293M	293.41M	293.41M	293.41M
Retained Earnings	7.2B	8.4B	7.14B	8.83B	9.45B	10.25B	10.83B	10.71B	10.92B	11.27B
Treasury Stock	-464.99M	-50.99M	-108.93M	-50.99M	-370.5M	0	0	0	0	0
Accumulated OCI	-1.22B	-1.25B	-1.49B	-1.2B	-1.04B	-2.21B	-1.31B	-388.47M	-975.17M	-328.55M
Minority Interest	556.9M	616.47M	1.01B	1.14B	1.27B	1.12B	1.28B	1.46B	1.21B	1.19B

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	1.79B	2.03B	2.19B	2.06B	2.57B	4.23B	2.49B	2.17B	2.63B	2.39B
Operating CF Margin %	0.12%	0.12%	0.12%	0.12%	0.15%	0.24%	0.14%	0.11%	0.14%	0.12%
Operating CF Growth %	0.17%	0.14%	0.08%	-0.06%	0.24%	0.65%	-0.41%	-0.13%	0.21%	-0.09%
Net Income	1.2B	1.47B	1.55B	2.23B	1.44B	1.44B	1.22B	894.33M	732.46M	740.87M
Depreciation & Amortization	655.81M	736.9M	736M	725M	1.59B	1.79B	1.62B	1.84B	1.75B	1.74B
Stock-Based Compensation	11.27M	28.69M	46.81M	10.74M	1.99M	0	0	0	32.52M	0
Deferred Taxes	-41.57M	-5.35M	-203.05M	89.17M	64.27M	111.1M	67.26M	-41.47M	-122.15M	-72.67M
Other Non-Cash Items	30.3M	-23.34M	156.24M	-99.92M	-518.52M	-335.14M	-322.7M	-395.77M	-327.27M	-468.62M
Working Capital Changes	-64.03M	-174.95M	-98M	-889M	-12.45M	1.24B	-97.77M	-128.07M	561.28M	444.31M
Change in Receivables	-302.99M	-305.92M	-86.25M	-170.49M	-64.11M	71.69M	-163.2M	-46.68M	-151.84M	-73.48M
Change in Inventory	-275.32M	-63.39M	-62.69M	-157.09M	-117.5M	-355.83M	-48.53M	-204.31M	-13.14M	107.9M
Change in Payables	526.99M	170.56M	518.74M	368.39M	-164.77M	1.37B	-363.95M	-356.79M	108.48M	155.59M
Cash from Investing+	-915.29M	-1.31B	-991.54M	-245.04M	-3.29B	-1.33B	-1.2B	-734.73M	-544.23M	-84.94M
Capital Expenditures	-1.73B	-1.94B	-1.78B	-2.06B	-1.12B	-1.05B	-854.36M	-723.99M	-684.6M	-699.36M
CapEx % of Revenue	0.11%	0.11%	0.1%	0.12%	0.06%	0.06%	0.05%	0.04%	0.04%	0.04%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	1.16B	1.53B	1.51B	1.98B	11.54M	15.58M	24.42M	36.2M	16.14M	14.1M
Cash from Financing+	-921.56M	-556.01M	-798.63M	-681.74M	-466.63M	-2.66B	-1.02B	-1.62B	-1.86B	-2.57B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-240.78M	-263.55M	-293.97M	-324.84M	-354.64M	-351.17M	-392.45M	-395.56M	-328.62M	-349.16M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-121.27M	273.26M	-138.39M	-480.61M	169.25M	-680.88M	-273.02M	-103.8M	-340.11M	-314.99M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	65.86M	93.18M	407M	2M	1.44B	3.18B	1.64B	1.44B	1.94B	1.69B
FCF Margin %	0%	0.01%	0.02%	0%	0.08%	0.18%	0.09%	0.07%	0.1%	0.09%
FCF Growth %	7.9%	0.41%	3.37%	-1%	720.08%	1.21%	-0.49%	-0.12%	0.35%	-0.13%
FCF per Share	0.11	0.15	0.66	0.00	1.63	3.59	1.40	1.23	3.31	2.87
FCF Conversion (FCF/Net Income)	1.90x	1.72x	1.71x	1.04x	2.14x	3.64x	2.57x	3.22x	5.27x	4.44x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	10.55%	11.45%	11.7%	16.7%	9.18%	9.11%	7.37%	4.58%	3.3%	3.52%
Return on Invested Capital (ROIC)	9.79%	10.59%	9.88%	12.76%	7.67%	6.96%	5.62%	4.26%	3.88%	4.09%
Gross Margin	31.85%	32.27%	33.76%	31.15%	30.87%	31.01%	27.09%	25.23%	25.32%	24.6%
Net Margin	6.15%	6.94%	7.2%	11.98%	6.86%	6.52%	5.5%	3.47%	2.57%	2.78%
Debt / Equity	0.83x	0.74x	0.69x	0.59x	1.04x	1.00x	0.95x	0.86x	0.81x	0.70x
Interest Coverage	4.65x	5.88x	5.68x	6.78x	4.62x	5.62x	5.24x	4.20x	3.22x	3.42x
FCF Conversion	1.90x	1.72x	1.71x	1.04x	2.14x	3.64x	2.57x	3.22x	5.27x	4.44x
Revenue Growth	17.59%	11.24%	4.42%	-6.96%	5.62%	2.19%	-1.35%	10.1%	0.29%	-0.61%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Health Care Services	-	-	-	-	-	-	-	-	15.39B	15.09B
Health Care Services Growth	-	-	-	-	-	-	-	-	-	-2.00%
Health Care Products	-	-	-	-	-	-	-	-	4.06B	4.25B
Health Care Products Growth	-	-	-	-	-	-	-	-	-	4.70%
Total FMC-AG and Co. KGaA	16.74B	17.91B	-	-	-	-	-	-	-	-
Total FMC-AG and Co. KGaA Growth	-	7.01%	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
North America	-	-	12.88B	11.57B	12.2B	12.48M	12.09M	13.57B	13.51B	13.67B
North America Growth	-	-	-	-10.16%	5.41%	-99.90%	-3.13%	112148.97%	-0.46%	1.19%
the World	-	-	-	-	-	-	-	5.34B	5.46B	5.19B
the World Growth	-	-	-	-	-	-	-	-	2.27%	-5.00%
Germany	400.4M	421.6M	-	-	-	-	-	487.28M	484.24M	478.96M
Germany Growth	-	5.30%	-	-	-	-	-	-	-0.62%	-1.09%
EMEA	-	-	-	-	2.69M	2.76M	2.77M	-	-	-
EMEA Growth	-	-	-	-	-	2.60%	0.07%	-	-	-
Asia Pacific	-	-	-	-	1.86M	1.89M	2.01M	-	-	-
Asia Pacific Growth	-	-	-	-	-	1.88%	6.12%	-	-	-
Latin America	-	-	-	-	709K	684K	703K	-	-	-
Latin America Growth	-	-	-	-	-	-3.53%	2.78%	-	-	-
Rest Of World Excluding Germany And North America	-	-	4.47B	-	-	-	-	-	-	-
Rest Of World Excluding Germany And North America Growth	-	-	-	-	-	-	-	-	-	-
D	-	-	433.11M	-	-	-	-	-	-	-
D Growth	-	-	-	-	-	-	-	-	-	-
Segment North America(Member)	11.81B	12.89B	-	-	-	-	-	-	-	-
Segment North America(Member) Growth	-	9.08%	-	-	-	-	-	-	-	-
Remaining World	4.52B	4.6B	-	-	-	-	-	-	-	-
Remaining World Growth	-	1.76%	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Fresenius Medical Care AG & Co. KGaA (FMS) has a price-to-earnings (P/E) ratio of 23.5x. This is roughly in line with market averages.

Growth & Financials

Fresenius Medical Care AG & Co. KGaA (FMS) reported $19.64B in revenue for fiscal year 2024. This represents a 99% increase from $9.87B in 2011.

Fresenius Medical Care AG & Co. KGaA (FMS) saw revenue decline by 0.6% over the past year.

Yes, Fresenius Medical Care AG & Co. KGaA (FMS) is profitable, generating $718.2M in net income for fiscal year 2024 (2.8% net margin).

Dividend & Returns

Yes, Fresenius Medical Care AG & Co. KGaA (FMS) pays a dividend with a yield of 2.75%. This makes it attractive for income-focused investors.

Fresenius Medical Care AG & Co. KGaA (FMS) has a return on equity (ROE) of 3.5%. This is below average, suggesting room for improvement.

Fresenius Medical Care AG & Co. KGaA (FMS) generated $1.78B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...